Olatec’s pharmaceutical platform is intended to address significant unmet needs in the treatment of inflammatory diseases. The Company’s Lead Compond, OLT1177TM dapansutrile is the only known selective NLRP3 inflammasome inhibitor in Phase 2 clinical trials in the US and Europe. In addition to OLT1177™ dapansutrile, Olatec’s platform includes more than 60 structurally related compounds (OLT Analogues). Based on clinical results and the expected market advantages of dapansutrile as well as data being generated from the OLT Analogues, Olatc’s platform has the potential not only to transform and expand markets, but also to represent a new class of pharmaceuticals for the treatment of inflammatory and other diseases.
